AlphaYou
Overview
Smart-money signal on REGN this 14d.
Key stats
Sep 5- Open
- $826.24
- 52-wk high
- $859.34
- High
- $854.49
- 52-wk low
- $538.24
- Low
- $825.77
- Prev close
- $823.82
- Mkt cap
- $85.22B
- P/E
- 20.9x
- Volume
- 749.5K
- Fwd P/E
- 15.4x
- Beta
- 0.19
- Div yield
- 0.43%
- P/S
- 5.5x
- P/B
- 2.8x
- Profit margin
- +27.9%
- Op margin
- +33.1%
- ROE
- +14.0%
What do analysts expect?
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsSmart money
8 funds hold a position and insiders have been net selling.
What funds are doing
Activist stakes, short interest & more
Earnings
Earnings came in 56.6% above what analysts expected.
Earnings per share
$8.00 expected
Revenue
No comparable estimate
Company adjusted EPS
From the company's release
The company and the analyst consensus count earnings differently, so the two figures differ. The comparison above uses the analyst basis.
Reports Oct 27, 2026, in 52 days
EPS expected
$14.53 to $17.68
Revenue expected
19 analysts
Last 30 days
Analysts raising estimates
Estimate drift
Change in 30 days
What the company said
Financials
What it sold, what it cost, what was left.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $3.75B | $3.88B | $3.61B | $4.29B |
| Cost of what it sold | $521.6M | $584.6M | $669.4M | $576.5M |
| Gross profit | $3.23B | $3.30B | $2.94B | $3.71B |
| What it spent | ||||
| Research and development | $1.56B | $1.63B | $1.65B | $1.63B |
| Sales and admin | $657.8M | $775.0M | $647.7M | $662.1M |
| Total operating expenses | $2.21B | $2.42B | $2.29B | $2.29B |
| What was left | ||||
| Operating profit | $1.03B | $879.9M | $642.9M | $1.42B |
| Interest on debt | $19.3M | $12.2M | $12.9M | $11.0M |
| Profit before tax | $1.76B | $1.04B | $831.2M | $1.53B |
| Tax | $303.3M | $199.1M | $104.0M | $230.9M |
| Net profit | $1.46B | $844.6M | $727.2M | $1.30B |
| EBITDA | $1.92B | $1.20B | $967.3M | $1.66B |
Technicals
Price structure
This stock is in a strong uptrend.
Trend
Strong uptrend
100 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
News
What the news says
Coverage is mixed
Tone of tracked coverage
Regeneron Pharmaceuticals stock hits 52-week high at $847.60
BullishSep 2Why is Uniqure NV stock gaining today?
NeutralSep 2Novartis’ and BMS’ paused CAR T trials, RevMed’s pancreatic cancer approval, more MFN deals
NeutralSep 2Gilead Sciences (WBAG:GILD) - Aandelenanalyse
Leans bullishSep 1RBC Capital maintains Regeneron stock rating on collaboration outlook
BullishSep 1CytomX Therapeutics to Present at Upcoming September Investor Conferences
NeutralSep 1REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today!
BearishSep 1Vitreoretinal Disorder Market Analysis Highlights Growth To $6.71 Billion By 2030 At 7.7% CAGR
Leans bullishAug 31
Macro
32 macro signals shaping REGN right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results